The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pre-Menstrual Syndrome Market Research Report 2025
Synopsis
Pre-menstrual syndrome (PMS) is defined as a condition that affects women at childbearing age and is characterized by symptoms such as bloating, pain, breast tenderness, body pain, fatigue, mood fluctuation, anxiety, etc.
The global Pre-Menstrual Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pre-Menstrual Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pre-Menstrual Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Pre-Menstrual Syndrome in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Pre-Menstrual Syndrome include Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd, McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc. and Umecrine Mood AB, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pre-Menstrual Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pre-Menstrual Syndrome.
Report Scope
The Pre-Menstrual Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pre-Menstrual Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pre-Menstrual Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alva-Amco Pharmacal Cos., Inc.
Bayer, Inc.
Chattem, Inc. (Sanofi)
DEKK-TEC, Inc.
G. R. Lane Health Products Ltd
McNeil Consumer Healthcare
MetP Pharma AG
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB
Novartis AG
GlaxoSmithKline Plc
Segment by Type
Analgesics (Pain Killers)
Oral Contraceptive Pills (OCPs)
Gonadotropin-Releasing Hormone (GnRH)
Antidepressants
Ovarian Suppressors
Diuretics
Benzodiazepines
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pre-Menstrual Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Pre-menstrual syndrome (PMS) is defined as a condition that affects women at childbearing age and is characterized by symptoms such as bloating, pain, breast tenderness, body pain, fatigue, mood fluctuation, anxiety, etc.
The global Pre-Menstrual Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pre-Menstrual Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pre-Menstrual Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Pre-Menstrual Syndrome in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Pre-Menstrual Syndrome include Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd, McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc. and Umecrine Mood AB, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pre-Menstrual Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pre-Menstrual Syndrome.
Report Scope
The Pre-Menstrual Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pre-Menstrual Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pre-Menstrual Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alva-Amco Pharmacal Cos., Inc.
Bayer, Inc.
Chattem, Inc. (Sanofi)
DEKK-TEC, Inc.
G. R. Lane Health Products Ltd
McNeil Consumer Healthcare
MetP Pharma AG
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB
Novartis AG
GlaxoSmithKline Plc
Segment by Type
Analgesics (Pain Killers)
Oral Contraceptive Pills (OCPs)
Gonadotropin-Releasing Hormone (GnRH)
Antidepressants
Ovarian Suppressors
Diuretics
Benzodiazepines
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pre-Menstrual Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pre-Menstrual Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Analgesics (Pain Killers)
1.2.3 Oral Contraceptive Pills (OCPs)
1.2.4 Gonadotropin-Releasing Hormone (GnRH)
1.2.5 Antidepressants
1.2.6 Ovarian Suppressors
1.2.7 Diuretics
1.2.8 Benzodiazepines
1.3 Market by Application
1.3.1 Global Pre-Menstrual Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pre-Menstrual Syndrome Market Perspective (2019-2030)
2.2 Pre-Menstrual Syndrome Growth Trends by Region
2.2.1 Global Pre-Menstrual Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pre-Menstrual Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Pre-Menstrual Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Pre-Menstrual Syndrome Market Dynamics
2.3.1 Pre-Menstrual Syndrome Industry Trends
2.3.2 Pre-Menstrual Syndrome Market Drivers
2.3.3 Pre-Menstrual Syndrome Market Challenges
2.3.4 Pre-Menstrual Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pre-Menstrual Syndrome Players by Revenue
3.1.1 Global Top Pre-Menstrual Syndrome Players by Revenue (2019-2024)
3.1.2 Global Pre-Menstrual Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Pre-Menstrual Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pre-Menstrual Syndrome Revenue
3.4 Global Pre-Menstrual Syndrome Market Concentration Ratio
3.4.1 Global Pre-Menstrual Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pre-Menstrual Syndrome Revenue in 2023
3.5 Pre-Menstrual Syndrome Key Players Head office and Area Served
3.6 Key Players Pre-Menstrual Syndrome Product Solution and Service
3.7 Date of Enter into Pre-Menstrual Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pre-Menstrual Syndrome Breakdown Data by Type
4.1 Global Pre-Menstrual Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Pre-Menstrual Syndrome Forecasted Market Size by Type (2025-2030)
5 Pre-Menstrual Syndrome Breakdown Data by Application
5.1 Global Pre-Menstrual Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Pre-Menstrual Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pre-Menstrual Syndrome Market Size (2019-2030)
6.2 North America Pre-Menstrual Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pre-Menstrual Syndrome Market Size by Country (2019-2024)
6.4 North America Pre-Menstrual Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pre-Menstrual Syndrome Market Size (2019-2030)
7.2 Europe Pre-Menstrual Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pre-Menstrual Syndrome Market Size by Country (2019-2024)
7.4 Europe Pre-Menstrual Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pre-Menstrual Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Pre-Menstrual Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pre-Menstrual Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Pre-Menstrual Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pre-Menstrual Syndrome Market Size (2019-2030)
9.2 Latin America Pre-Menstrual Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pre-Menstrual Syndrome Market Size by Country (2019-2024)
9.4 Latin America Pre-Menstrual Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pre-Menstrual Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Pre-Menstrual Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pre-Menstrual Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Pre-Menstrual Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alva-Amco Pharmacal Cos., Inc.
11.1.1 Alva-Amco Pharmacal Cos., Inc. Company Detail
11.1.2 Alva-Amco Pharmacal Cos., Inc. Business Overview
11.1.3 Alva-Amco Pharmacal Cos., Inc. Pre-Menstrual Syndrome Introduction
11.1.4 Alva-Amco Pharmacal Cos., Inc. Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.1.5 Alva-Amco Pharmacal Cos., Inc. Recent Development
11.2 Bayer, Inc.
11.2.1 Bayer, Inc. Company Detail
11.2.2 Bayer, Inc. Business Overview
11.2.3 Bayer, Inc. Pre-Menstrual Syndrome Introduction
11.2.4 Bayer, Inc. Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.2.5 Bayer, Inc. Recent Development
11.3 Chattem, Inc. (Sanofi)
11.3.1 Chattem, Inc. (Sanofi) Company Detail
11.3.2 Chattem, Inc. (Sanofi) Business Overview
11.3.3 Chattem, Inc. (Sanofi) Pre-Menstrual Syndrome Introduction
11.3.4 Chattem, Inc. (Sanofi) Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.3.5 Chattem, Inc. (Sanofi) Recent Development
11.4 DEKK-TEC, Inc.
11.4.1 DEKK-TEC, Inc. Company Detail
11.4.2 DEKK-TEC, Inc. Business Overview
11.4.3 DEKK-TEC, Inc. Pre-Menstrual Syndrome Introduction
11.4.4 DEKK-TEC, Inc. Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.4.5 DEKK-TEC, Inc. Recent Development
11.5 G. R. Lane Health Products Ltd
11.5.1 G. R. Lane Health Products Ltd Company Detail
11.5.2 G. R. Lane Health Products Ltd Business Overview
11.5.3 G. R. Lane Health Products Ltd Pre-Menstrual Syndrome Introduction
11.5.4 G. R. Lane Health Products Ltd Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.5.5 G. R. Lane Health Products Ltd Recent Development
11.6 McNeil Consumer Healthcare
11.6.1 McNeil Consumer Healthcare Company Detail
11.6.2 McNeil Consumer Healthcare Business Overview
11.6.3 McNeil Consumer Healthcare Pre-Menstrual Syndrome Introduction
11.6.4 McNeil Consumer Healthcare Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.6.5 McNeil Consumer Healthcare Recent Development
11.7 MetP Pharma AG
11.7.1 MetP Pharma AG Company Detail
11.7.2 MetP Pharma AG Business Overview
11.7.3 MetP Pharma AG Pre-Menstrual Syndrome Introduction
11.7.4 MetP Pharma AG Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.7.5 MetP Pharma AG Recent Development
11.8 Pherin Pharmaceuticals, Inc.
11.8.1 Pherin Pharmaceuticals, Inc. Company Detail
11.8.2 Pherin Pharmaceuticals, Inc. Business Overview
11.8.3 Pherin Pharmaceuticals, Inc. Pre-Menstrual Syndrome Introduction
11.8.4 Pherin Pharmaceuticals, Inc. Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.8.5 Pherin Pharmaceuticals, Inc. Recent Development
11.9 Umecrine Mood AB
11.9.1 Umecrine Mood AB Company Detail
11.9.2 Umecrine Mood AB Business Overview
11.9.3 Umecrine Mood AB Pre-Menstrual Syndrome Introduction
11.9.4 Umecrine Mood AB Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.9.5 Umecrine Mood AB Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Detail
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Pre-Menstrual Syndrome Introduction
11.10.4 Novartis AG Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.10.5 Novartis AG Recent Development
11.11 GlaxoSmithKline Plc
11.11.1 GlaxoSmithKline Plc Company Detail
11.11.2 GlaxoSmithKline Plc Business Overview
11.11.3 GlaxoSmithKline Plc Pre-Menstrual Syndrome Introduction
11.11.4 GlaxoSmithKline Plc Revenue in Pre-Menstrual Syndrome Business (2019-2024)
11.11.5 GlaxoSmithKline Plc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
